MUMBAI, May 29 (Reuters) - Sun Pharmaceutical Industries Ltd , India's largest drugmaker by sales, reported fourth-quarter profit well below analysts' expectations, hit by costs related to integrating smaller rival Ranbaxy Laboratories Ltd .
MUMBAI, May 14 (Reuters) - Indian generic drugmaker Ranbaxy Laboratories Ltd has been sued in a district court in the United States for allegedly manipulating U.S. Food and Drug Administration rules for years to keep rival generic drugs out of the market.
* Sun Pharma looking to buy overseas biosimilar assets - bankers
Sun Pharmaceuticals Industries and Ranbaxy , came through earlier this week ..... positive on the merger, as we believe Ranbaxy 's OTC and specialty drugs portfolio ..... are also present in the acquired Ranbaxy business. We believe the stock is
Quarterly revenue for the yet-to-merge Ranbaxy business was up 16% and profit turned ..... prior period and accounted for 44% of Ranbaxy 's quarterly sales). We believe ..... further enhanced with the addition of Ranbaxy to its portfolio.
largely the result of incorporating Ranbaxy financials into our forecast starting 1 April 2014. We believe the Ranbaxy acquisition will strengthen Sun ..... to expand the operating margins of Ranbaxy post-merger. These include manufacturing
fair value estimate for Sun Pharmaceuticals as we update our model for recent performance and integrate the acquisition of Ranbaxy into our forecast. We also are maintaining our narrow moat rating for the company. Sun continues to post strong growth
April bought Ranbaxy Laboratories for $4 billion from Japan’s Daiichi Sankyo . And French pharmaceutical ..... purchase of Ranbaxy Laboratories , the latter ..... Japan’s Daiichi Sankyo in 2008 bought a 64% stake in Ranbaxy for $4.2
but we remain concerned about possible margin pressure from internal regulatory issues and the upcoming integration of Ranbaxy . Sun's U.S. business continued to lead the charge with 43% growth, as currency benefits and pricing power in many
acquire the ailing Indian pharmaceutical company Ranbaxy in an all-equity transaction. Each Ranbaxy shareholder will receive 0.8 shares of Sun ..... quality control and regulatory problems plaguing Ranbaxy 's recent performance. Assuming Sun can successfully